The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Emmecell has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to EO2002, the company’s investigational magnetic human corneal endothelial cell therapy for the treatment of
RMAT designation is intended to expedite the development and review of regenerative medicine therapies for serious conditions where clinical evidence indicates the potential to address an unmet medical need.1 The designation provides opportunities for early and frequent FDA interactions to help accelerate clinical development, manufacturing discussions, and regulatory review.1
EO2002 is an investigational allogeneic cultured human corneal endothelial cell therapy that utilizes Emmecell's proprietary magnetic cell delivery platform, which is designed to enhance the localization and retention of therapeutic cells following administration.1 The therapy is intended to restore corneal endothelial function without the need for donor tissue transplantation or invasive endothelial keratoplasty, addressing the growing clinical need created by limited donor tissue availability and the surgical burden associated with standard-of-care corneal transplantation.1,2 EO2002 is currently being evaluated in the EMERALD clinical trial (NCT04894110).1
KEY FACTS
"RMAT designation represents an important regulatory milestone for EO2002 and underscores the potential of our Magnetic Cell Delivery platform to address a meaningful unmet need in corneal endothelial disease," said Ramin Valian, chief executive officer of Emmecell, in the announcement. "We are encouraged by the clinical evidence generated to date and look forward to continued collaboration with the FDA as we advance the EMERALD study."1
In June 2026, Emmecell announced the closing of a strategic financing round that included participation from Bausch + Lomb, with proceeds designated to support the continued advancement of its clinical programs and expansion of its magnetic cell delivery platform.2 Valian joined Emmecell as chief executive officer in January 2026, bringing more than 20 years of global commercial and strategic leadership in eye care—spanning corneal disease, surgical and interventional glaucoma, retina, and consumer eye care—including prior roles at Allergan and AbbVie.3
In addition to its corneal endothelial program, Emmecell is also advancing a cell therapy for
